1 STATE OF OKLAHOMA
1
2 1st Session of the 59th Legislature (2023)
2
3 SENATE BILL 668 By: Standridge
3
4
4
5
5
6 AS INTRODUCED
6
7 An Act relating to the Uniform Controlled Dangerous
7 Substances Act; amending 63 O.S. 2021, Section 2-322,
8 which relates to precursor substances requiring
8 permit or license; removing certain drugs from
9 requiring certain permitting or licensing; amending
9 63 O.S. 2021, Section 2-210, which relates to
10 Schedule IV; including certain drug; and providing an
10 effective date.
11
11
12
12
13 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
13
14 SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-322, is
14
15 amended to read as follows:
15
16 Section 2-322. A. No person or business shall possess, sell,
16
17 manufacture, transfer, or otherwise furnish any of the following
17
18 precursor substances without first having a permit or license issued
18
19 by the Director of the Oklahoma State Bureau of Narcotics and
19
20 Dangerous Drugs Control, except as provided in Section 2-327 of this
20
21 title:
21
22 1. D-Lysergic acid;
22
23 2. Ergotamine and its salts;
23
24 3. Ergonovine and its salts;
24
Req. No. 307 Page 1
 1 4. Methylamine;
1
2 5. Ethylamine;
2
3 6. Phenyl-2-Propanone;
3
4 7. Phenylacetic acid and its salts;
4
5 8. Ephedrine, its salts, optical isomers and salts of optical
5
6 isomers;
6
7 9. Norpseudoephedrine, its salts, optical isomers, and salts of
7
8 optical isomers;
8
9 10. Phenylpropanolamine, its salts, optical isomers and salts
9
10 of optical isomers;
10
11 11. 9. Benzyl cyanide;
11
12 12. 10. N-methylephedrine, its salts, optical isomers and salts
12
13 of optical isomers;
13
14 13. Pseudoephedrine, its salts, optical isomers and salts of
14
15 optical isomers;
15
16 14. 11. Chloroephedrine, its salts, optical isomers and salts
16
17 of optical isomers;
17
18 15. 12. Piperidine and its salts;
18
19 16. 13. Pyrrolidine and its salts;
19
20 17. 14. Propionic anhydride;
20
21 18. 15. Isosafrole;
21
22 19. 16. Safrole;
22
23 20. 17. Piperonal; and
23
24 21. 18. Red Phosphorus.
24
Req. No. 307 Page 2
 1 B. Upon completion of an application for a license pursuant to
1
2 Section 2-323 of this title, or a permit pursuant to Section 2-324
2
3 of this title, the Director of the Oklahoma State Bureau of
3
4 Narcotics and Dangerous Drugs Control shall either grant or deny
4
5 such license or permit. A denial of an application for a permit or
5
6 license shall be handled as provided by Section 2-325 of this title.
6
7 SECTION 2. AMENDATORY 63 O.S. 2021, Section 2-210, is
7
8 amended to read as follows:
8
9 Section 2-210. A. Any material, compound, mixture, or
9
10 preparation which contains any quantity of the following substances
10
11 having a potential for abuse associated with a stimulant or
11
12 depressant effect on the central nervous system:
12
13 1. Chloral betaine;
13
14 2. Chloral hydrate;
14
15 3. Ethchlorvynol;
15
16 4. Ethinamate;
16
17 5. Meprobamate;
17
18 6. Paraldehyde;
18
19 7. Petrichloral;
19
20 8. Diethylpropion;
20
21 9. Phentermine;
21
22 10. Pemoline;
22
23 11. Chlordiazepoxide;
23
24
24
Req. No. 307 Page 3
 1 12. Chlordiazepoxide and its salts, but not including
1
2 chlordiazepoxide hydrochloride and clidinium bromide or
2
3 chlordiazepoxide and water-soluble esterified estrogens;
3
4 13. Diazepam;
4
5 14. Oxazepam;
5
6 15. Clorazepate;
6
7 16. Flurazepam and its salts;
7
8 17. Clonazepam;
8
9 18. Barbital;
9
10 19. Mebutamate;
10
11 20. Methohexital;
11
12 21. Methylphenobarbital;
12
13 22. Phenobarbital;
13
14 23. Fenfluramine;
14
15 24. Pentazocine;
15
16 25. Propoxyphene;
16
17 26. Butorphanol;
17
18 27. Alprazolam;
18
19 28. Halazepam;
19
20 29. Lorazepam;
20
21 30. Prazepam;
21
22 31. Temazepam;
22
23 32. Triazolam;
23
24 33. Carisoprodol;
24
Req. No. 307 Page 4
 1 34. Dichloralphenazone;
1
2 35. Estazolam;
2
3 36. Eszopiclone;
3
4 37. Midazolam;
4
5 38. Modafinil;
5
6 39. Zaleplon;
6
7 40. Zolpidem;
7
8 41. Tramadol;
8
9 42. Bromazepam;
9
10 43. Suvorexant;
10
11 44. Phenazepam;
11
12 45. Etizolam; or
12
13 46. Clonazolam; or
13
14 47. Xylazine.
14
15 B. 1. The following nonnarcotic substances, which may, under
15
16 the Federal Food, Drug, and Cosmetic Act (21 U.S.C., Section 301),
16
17 be lawfully sold over the counter without a prescription, are
17
18 excluded from all schedules of controlled substances under this
18
19 title:
19
20 a. Breathe-Aid,
20
21 b. BronCare,
21
22 c. Bronchial Congestion,
22
23 d. Bronkaid Tablets,
23
24 e. Bronkaid Dual Action Caplets,
24
Req. No. 307 Page 5
 1 f. Bronkotabs,
1
2 g. Bronkolixir,
2
3 h. NeoRespin,
3
4 i. Pazo Hemorrhoid Ointment and Suppositories,
4
5 j. Primatene Tablets,
5
6 k. Primatene “Dual Action” Formula,
6
7 l. Quelidrine,
7
8 m. Resp, and
8
9 n. Vatronal Nose Drops.
9
10 2. At the request of any person, the Director may exempt any
10
11 other drug product containing ephedrine from being included as a
11
12 Schedule IV controlled substance if such product:
12
13 a. is labeled and marketed in a manner consistent with
13
14 the pertinent OTC tentative final or final monograph
14
15 issued by the FDA, and
15
16 b. is manufactured and distributed for legitimate
16
17 medicinal use and in a manner that reduces or
17
18 eliminates the likelihood of abuse.
18
19 3. In making a determination regarding a drug product, the
19
20 Director, after notice and hearing, shall consider the following:
20
21 a. the history and current pattern of abuse,
21
22 b. the name and labeling of the product,
22
23 c. the intended manner of distribution, advertising and
23
24 promotion of the product, and
24
Req. No. 307 Page 6
 1 d. other factors as may be relevant to and consistent
1
2 with the public health and safety.
2
3 4. The hearing shall be held in accordance with the
3
4 Administrative Procedures Act.
4
5 5. A list of current drug products meeting exemption
5
6 requirements under this subsection may be obtained from the Bureau
6
7 upon written request.
7
8 C. The Board of Pharmacy may except by rule any compound,
8
9 mixture, or preparation containing any depressant substance listed
9
10 in subsection A of this section from the application of all or any
10
11 part of the Uniform Controlled Dangerous Substances Act, Section 2-
11
12 101 et seq. of this title, if the compound, mixture, or preparation
12
13 contains one or more active medicinal ingredients not having a
13
14 depressant effect on the central nervous system, and if the
14
15 admixtures are included therein in combinations, quantity,
15
16 proportion, or concentration that vitiate the potential for abuse of
16
17 the substances which have a depressant effect on the central nervous
17
18 system.
18
19 SECTION 3. This act shall become effective November 1, 2023.
19
20
20
21 59-1-307 JES 1/18/2023 11:32:24 AM
21
22
22
23
23
24
24
Req. No. 307 Page 7